0 316

Cited 0 times in

Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen

Authors
 Seung-Hoon Beom  ;  Jong Gwang Kim  ;  Seung Hyuk Baik  ;  Seong Hoon Shin  ;  Inkeun Park  ;  Young Suk Park  ;  Myung-Ah Lee  ;  Soohyeon Lee  ;  So-Yeon Jeon  ;  Sae-Won Han  ;  Myoung Hee Kang  ;  Jisu Oh  ;  Jin Soo Kim  ;  Jin Young Kim  ;  Mi Sun Ahn  ;  Dae Young Zang  ;  Byung-Noe Bae  ;  Hong Jae Jo  ;  Hee Kyung Kim  ;  Jung-Han Kim  ;  Ji Ae Yoon  ;  Dong Han Kim 
Citation
 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.149(3) : 1131-1143, 2023-03 
Journal Title
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
ISSN
 0171-5216 
Issue Date
2023-03
MeSH
Antineoplastic Combined Chemotherapy Protocols / therapeutic use ; Bevacizumab / therapeutic use ; Camptothecin / therapeutic use ; Colonic Neoplasms* / drug therapy ; Colorectal Neoplasms* / pathology ; Fluorouracil / therapeutic use ; Humans ; Leucovorin / therapeutic use ; Male ; Oxaliplatin / therapeutic use ; Rectal Neoplasms* / drug therapy ; Republic of Korea
Keywords
Acquired resistance ; Anti-VEGF agents ; Chemotherapy ; Colorectal cancer
Abstract
Purpose: To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen. Methods: This was a prospective observational study conducted at 22 sites across Korea between February 2018 and September 2019. Patients aged > 19?years with a diagnosis of mCRC who were prescribed aflibercept plus FOLFIRI, after progression with an oxaliplatin-containing regimen were included. Disease assessment was performed every 6?weeks. Results: A total of 185 patients were included (males, 58.9%; right-sided tumors, 23.8%; and ECOG performance factor ≥ 1, 68.6%). A total of 514 adverse events (AEs) occurred in 134 patients, of which 206 (49.2%; 95% CI 42.0%, 56.4%) events were considered as adverse drug reactions (ADRs), 172 unexpected AEs (49.7%; 95% CI 42.5%, 56.9%), and 53 serious AEs (22.2%; 95% CI16.2%, 28.2%). The most common serious ADR was pneumonia (n = 2, 1.6%). The most common all grade hematological AE and non-hematological AE were neutropenia (21.6%) and nausea (16.2%), respectively. Over a median follow-up of 5.6?months, a total of five grade 5 (1.0%) AEs were reported. Median OS was 9.4?months, and median progression-free survival (PFS) was 7.3?months. The overall response rate was 14.6%. Right-sided tumor location and prior bevacizumab treatment were independent factors of poor PFS in multivariate analysis. Conclusion: Aflibercept in combination with FOLFIRI was effective and showed an acceptable safety profile in Korean patients with mCRC in daily clinical practice.
Full Text
https://link.springer.com/article/10.1007/s00432-022-03946-x
DOI
10.1007/s00432-022-03946-x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Baik, Seung Hyuk(백승혁) ORCID logo https://orcid.org/0000-0003-4183-2332
Beom, Seung Hoon(범승훈) ORCID logo https://orcid.org/0000-0001-7036-3753
Oh, Jisu(오지수)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/194102
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links